Skip to content

Palvella Therapeutics PVLA Other income, net (Note 6)

Other income, net (Note 6) at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$5.3M-32.1%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$651K-429%
Precigen logo
PrecigenPGEN
$290K+4,043%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-$20K-110%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$22K-320%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$1.18M+53.0%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.7B+468%
Enterprise value$1.5B
P/S41.6×

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's other income, net (note 6)?
Palvella Therapeutics (PVLA) reported other income, net (note 6) of -$32K in Q1 2026.
How has Palvella Therapeutics's other income, net (note 6) changed year-over-year?
Palvella Therapeutics's other income, net (note 6) decreased by 114.3% year-over-year, from $224K to -$32K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.